Novo Nordisk A/S
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Maziar Mike Doustdar
- Full Time Employees
- 68,794
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- Novo Alle 1 Bagsvaerd CR Denmark 2880
- IPO Date
- Apr 30, 1981
- CIK
- 0000353278
- Website
- novonordisk.com
- Similar Companies
- Business
- Novo Nordisk A/S, a leading global healthcare company founded in 1923 and headquartered in Bagsværd, Denmark, develops, manufactures and markets pharmaceutical products and services focused on diabetes care, obesity management, rare blood disorders, growth hormone therapy and hormone replacement therapy; its core offerings include GLP-1 receptor agonists such as semaglutide branded as Ozempic and Rybelsus for type 2 diabetes and Wegovy for obesity, insulins including rapid-acting NovoLog/NovoRapid, long-acting Tresiba and Levemir, and human insulins like Novolin R, alongside hemostasis products such as NovoSeven and NovoEight for hemophilia, and growth hormone therapies; the company operates production facilities in nine countries, employs over 76,000 people and markets its products in approximately 170 countries worldwide, with majority control held by Novo Holdings A/S, a wholly owned entity of the Novo Nordisk Foundation. Recent strategic developments include the October 2025 acquisition of Akero Therapeutics for up to $5.2 billion to bolster its metabolic dysfunction-associated steatohepatitis (MASH) pipeline, a May 2025 partnership and licensing agreement with Septerna potentially worth $2.2 billion for oral small molecule therapies targeting obesity, type 2 diabetes and cardiometabolic disorders, a December 2024 collaboration with Photys Therapeutics for up to $186 million in proximity-based therapeutics for cardiometabolic targets, filing for FDA approval of a higher 7.2 mg dose of Wegovy injection in November 2025, positive phase 2 results for amycretin showing significant weight loss and HbA1c reduction in type 2 diabetes patients in November 2025, and workforce reduction of 9,000 positions or about 9% globally in September 2025 amid competitive pressures from generic entrants; the company continues expanding manufacturing capacity, including a $4.1 billion semaglutide plant in Clayton, North Carolina announced in June 2024 and acquisition of Catalent sites, while appointing Maziar Mike Doustdar as CEO effective August 2025.
Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating?
Can Novo Nordisk's GLP-1 Pill Momentum Offset LLY's Growing Edge?
Novo CEO says obesity market won't be winner-take-all battle with Lilly
Novo Nordisk CEO Mike Doustdar sits down with Jim Cramer
Novo Nordisk CEO defends lawsuit against Eli Lilly: 'Competition has to be fair'
Berenberg Cuts Novo Nordisk as Lilly Takes the Oral Market
Novo Nordisk CEO sees ‘long runway' for weight-loss drugs as obesity grips America
Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?
PHARMA BETS: CEO turns to AI for next-generation drugs
The Market Is (Still) Underestimating Novo Nordisk
Here Are Wednesday’s Top Wall Street Analyst Research Calls: The Gap, Genmab, Hilton Worldwide, Intuitive Surgical, Marriott International, Merck, Novo Nordisk, Okta, and More
Novo Nordisk Stock: Buy or Sell?
Better Buy: Eli Lilly vs. Novo Nordisk
First Trust Advisors LP Lowers Stock Holdings in Novo Nordisk A/S $NVO
Novo Nordisk A/S Q2 Earnings Call Highlights
Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem
Novo Nordisk Stock Rises After GLP-1 Antitrust Win
Novo Nordisk: Dismal Q2 Earnings, Operational Frailties Warrant Rating Downgrade
Why Is Everyone Talking About Novo Nordisk?
Novo Nordisk: The Market Has Lost Its Mind, Too Cheap To Ignore